Pluri Inc (PLUR) News & EventsPLURPluri Inc

Pluri Enters Agreement to Sell 2.2 Million Shares

Pluri announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor, for the purchase and sale of 2,228,940 common shares at a purchase price of $1.50 per share in a registered direct offering. The gross proceeds from the offering are expected to be approximately $3.3M, before deducting placement agent commissions and other offering expenses. In addition, in a concurrent private placement, Pluri will issue and sell unregistered warrants to purchase up to 2,228,940 common shares. The Warrants will have an exercise price of $1.65 per share, will be initially exercisable six months following the date of issuance, and will expire five and a half years from the date of issuance. The closing of the offering is expected to occur on or about August 28. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

Pluri Chairman Invests Over $17 Million

Pluri provided an update on the cumulative investment and ownership position of its chairman, Alejandro Weinstein. The company said, "Over the past year, Mr. Weinstein has invested more than $17 million in Pluri through a series of investments, including a $1.25 million advance investment made in June 2026 pursuant to an Advance Subscription Agreement, as disclosed in the Company's Form 8-K filed on June 22, 2026. Mr. Weinstein currently owns more than 30% of the Company's issued and outstanding shares. His growing commitment comes as Pluri advances its transition from platform development toward commercial execution, with an increasing focus on longevity and planned commercial activity in the United States. Alongside this strategic progress, Pluri is seeing strong inbound interest from multiple U.S. parties exploring potential product purchases and technology collaborations based on the Company's capabilities in reproducible cell production, tailored exosomes and other unique biological components. Mr. Weinstein is a global investor and entrepreneur with more than two decades of experience across pharmaceuticals, biotechnology and wellness. As previously reported by Pluri, he has participated in more than 20 M&A transactions and over $5 billion in exits, including transforming CFR Pharmaceuticals into a multinational group acquired by Abbott for approximately $2.9 billion. He began building his position in Pluri after identifying its proprietary 3D cell-expansion platform as a differentiated technology with broad potential and became Chairman of the Board in December 2025. His interest in the company is based on Pluri's ability to translate its scientific and technological capabilities into commercial opportunities. As Chairman, Mr. Weinstein has supported a strategic focus on commercialization, disciplined resource allocation and execution across the Company's platform and business verticals. Pluri is now advancing commercial initiatives in the United States and other markets, reflecting its broader transition from platform development toward commercial operations."

Pluri Chairman Invests $2.5M at 30% Premium

Pluri announced that an entity beneficially owned by Alejandro Weinstein, chairman of the board and one of the company's largest shareholders, has entered into a securities purchase agreement with Pluri for an additional $2.5M investment in the company at a 30% premium to the market price on March 24. This additional investment follows Weinstein's prior $2.5M investment announced in connection with his appointment as chairman of the board. The securities purchase agreement relates to a private placement offering consisting of: 625,000 common shares, par value $0.00001 per share of the company, and warrants to purchase up to 625,000 common shares of the company. The combined purchase price for each common share and common warrant is $4.00. The warrants are exercisable immediately upon closing of the transaction at an exercise price of $4.25 per share and will be exercisable until the expiration of the eighteen-month anniversary of the closing of the transaction. The gross proceeds to the company from this transaction are expected to be approximately $2.5M. Pluri intends to use the proceeds from the private placement for general working capital and general corporate purposes.